John Hopkin’s University Publishes Efficacy of QuadraMune Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies

By AIT News Desk On May 28, 2022

Commercially Available Nutraceutical Developed by Phase III Stem Cell Biotechnology Company Continues to Receive Independent Validation of Potential Benefit in SARS-CoV-2 Strains

Therapeutic Solutions International, a clinical-stage biotechnology company, commented on a recent research report from John Hopkins Children’s Center in the peer-reviewed publication Nature journal Communications Biology¹.

Latest Aithority Insights: Iteris Announces Availability of Customizable Enhanced Mobility Data

“Science is a force that cannot be stopped, we are fortunate to have internationally renowned scientists as part of our team, who develop out of the box ideas such as QuadraMune, which are now in the process of being validated internally and externally.”

Data generated by the researchers independent of Therapeutic Solutions International, unequivocally demonstrated that sulforaphane, one of the ingredients in the Company’s QuadraMune™ product, suppresses multiplication and activity of SARS-CoV-2, the virus responsible for Covid-19.

In the publication abstract, the researchers concluded, “Our results suggest that sulforaphane should be explored as a potential agent for the prevention or treatment of coronavirus infections.”

Browse The Complete News About Aithority : Veniam and Single Digits Connect Mobile IoT Devices to Millions of Wi-Fi Hotspots

“As a physician who is currently leading an FDA-cleared Phase III clinical trial for advanced COVID-19 patients, I am extremely excited to see that our nutraceutical program is receiving independent validation based on research published from world-class institutions,” said Dr. James Veltmeyer, Chief Medical Officer of the Company.

The Company possesses two issued United States Patents for use of QuadraMune in the area of Immune Modulation (#11,229,674) and treatment of Coronavirus (#11,266,707). After the Company filed its first patent on QuadraMune on May 5th, 2020, numerous independent publications appeared supporting the use of the four ingredients in QuadraMune for treatment of COVID-19².

“Our successes are based on the fact that we at Therapeutic Solutions International are focused number one on science and leveraging science to help people,” said Timothy Dixon, President, and CEO of the Company. “Science is a force that cannot be stopped, we are fortunate to have internationally renowned scientists as part of our team, who develop out of the box ideas such as QuadraMune, which are now in the process of being validated internally and externally.”

[To share your insights with us, please write to sghosh@martechseries.com]